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Abstract
Objective: Two chromosomal instability (CIN) pathways
are described in glioblastoma multiforme (GBM), type 1
and type 2, which can be observed in up to 70% of the
cases. Microsatellite instability (MSI) plays a pathogenic
role in sporadic cancers such as colon, gastric and endo-
metrial carcinomas with deficient mismatch repair
(MMR). We aimed to perform a comprehensive analysis
of the relationship between CIN and MSI mechanisms in
sporadic glioblastomas. Methods: 129 GBMs were ex-
amined (109 newly diagnosed and 20 relapses) investi-
gating MSI, immunohistochemical expression of MMR
proteins as well as sequencing and promoter methyl-
ation of hMLH1. We characterized the molecular changes
frequently correlated with CIN in MSI+ GBMs and com-
pared them with 26 microsatellite-stable tumors. Re-
sults: Low-level MSI was observed in 11 of 129 (8.5%)
cases and was higher in relapses than in primary GBMs
(25 vs. 5.5%, p = 0.027). High-level MSI was not found in
any case. A deficient expression of MLH1 and PMS2
without hMLH1 inactivation was observed only in one
giant cell GBM. 55% of the MSI+ GBMs showed a profile
which did not correspond to one of the known CIN path-
ways. An inverse association was observed between
MSI and mutations of both p53 and PTEN. Conclusions:
Our data suggest that CIN and MSI contribute to the
genomic instability in GBMs via independent pathways.
Since MSI was significantly more frequent in relapses, it
might play a role in the malignant progression of GBM.
Copyright © 2004 S. Karger AG, Basel
Introduction
Genomic instability plays a key role in the pathogene-
sis of numerous solid tumors [1, 2]. One form is chromo-
somal instability (CIN), characterized by multiple gains
and losses in specific chromosome regions [1]. In glioblas-
toma multiforme (GBM), the most frequent primary
brain tumor in adults [3, 4], CIN was observed to be con-
nected with two pathways, typically harboring either mu-
tations of p53 or amplification of the epidermal growth
factor receptor (EGFR) oncogene. This condition was
termed type 1 and type 2 GBM, respectively [5–9]. How-
ever, about 30% of GBMs show molecular alterations that
correspond neither to type 1 nor to type 2 pathways [5, 10,
11].
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A second form of genomic instability, microsatellite
instability (MSI), typically displays length mutations in
microsatellite sequences in noncoding and in coding re-
gions of genes such as PTEN, TGFßR-II, IGFIIR, BAX
and E2F4 [12–15]. MSI was suggested to be the conse-
quence of the inactivation of mismatch repair (MMR)
genes [12, 13, 16] and was observed in hereditary syn-
dromes, i.e. hereditary nonpolyposis colorectal cancer
(HNPCC) with a frequency of up to 90% [13, 16], and
sporadic malignancies such as colorectal (15%) [17], en-
dometrial (15%) [18], non-small-cell lung (35%) [19],
head and neck (28%) [20], gastric (10%) [21] or prostate
cancers (8.5%) [22]. In sporadic tumors, MSI was found
to be most frequently caused by hMLH1 promoter hyper-
methylation [23]. The relevance of MSI in sporadic can-
cers is confirmed by molecular and clinicopathological
observations such as an inverse relationship between MSI
and p53 mutations in gastric cancer [19] and colorectal
cancer cell lines [24], the association of MSI with the
malignant progression in gastric tumors [25] and meta-
static gastric cancers [26] or the distinct histopathological
features of MSI+ colorectal cancer compared to their MSS
(microsatellite-stable) homologues [27].
A comprehensive analysis of the molecular basis of
MSI and the relationship with the CIN-mediated path-
ways has not been performed in glioblastoma. MSI was
described in GBM in some previous studies but either
small tumor series are available or only few polymorphic
repeats were used. Therefore, we investigated 129 sporad-
ic GBMs for MSI using 15 polymorphic repeats and per-
formed immunohistochemistry for the MMR proteins
hMLH1, hPMS2, hMSH2 and hMSH6, mutational anal-
ysis of hMLH1 as well as evaluation of hMLH1 promoter
methylation. To elucidate the (in)dependence of MSI and
the CIN, we carried out loss of heterozygosity (LOH) stud-
ies at loci involved in GBM pathogenesis, mutational
screening of p53 and PTEN and investigated EGFR am-
plification in both MSI and MSS tumors.
Material and Methods
GBM Samples
129 paired samples of blood and tumor tissue were obtained from
GBM patients treated at the Department of Neurosurgery of the Uni-
versity of Dresden. Portions of the fresh tumor samples were frozen
in liquid nitrogen and stored at –80°C. Tumor tissue was evaluated
at the Institute of Pathology, University of Dresden, Germany,
according to the World Health Organization (WHO) criteria [3]. For-
malin-fixed, paraffin-embedded specimens were used for immuno-
histochemistry. Leukocyte and tumor DNA were isolated applying
the QIAamp® DNA Mini Kit (Qiagen, Hilden, Germany). This study
was conducted with the consent of the institutional ethics committee
and an informed consent from each patient or his/her caretaker was
obtained.
MSI Analysis
Matched genomic tumor and blood DNA were amplified by PCR
using 15 primer pairs [28, 29]: mononucleotides (BAT25, BAT26,
BAT40, TGß-RIIpA, GTBPIn5, GTBPIn9), dinucleotides (D5S346,
D17S250, D10S197, D2S123, D18S58, D13S153, D3S1300,
D3S1619) and a tetranucleotide (MYCL1). PCR was performed
using 50–100 ng of template DNA. Amplified PCR products were
electrophoresed on a 6.5% Long Ranger polyacrylamide gel on an
Automated Laser Fluorescence (ALF express®) sequencing device
(Amersham Pharmacia Biotech, Freiburg, Germany) and analyzed
using the ALLELELINKS® 1.00 software (Amersham Pharmacia
Biotech). MSI was defined by the presence of novel alleles in tumor
DNA that were absent in corresponding leukocyte DNA [30] and
confirmed in two independent analyses. Informative dinucleotide
repeats without MSI were assessed for LOH as described [31, 32].
Three categories were defined according to the MSI findings: high-
level MSI (MSI-H, 640% of studied loci altered), low-level MSI
(MSI-L, !40%) and MSS (no analyzed marker unstable) [27, 28,
33].
Immunohistochemistry of MMR Proteins
Immunostaining for hMLH1 (clone G168-15, PharMingen Int.,
San Diego, Calif., USA), hMSH2 (clone FE11, Oncogene Res. Prod-
ucts, Cambridge, Mass., USA), hMSH6 (clone 44, Transduction
Lab., Lexington, UK) and hPMS2 (A16-4, PharMingen Int., San Die-
go, Calif., USA) was performed in all MSI+ tumors as described [34].
Tumor cells exhibiting no or reduced nuclear staining were consid-
ered as having an abnormal pattern. The relative densitometry of
MMR protein expression (compared to the negative controls) was
performed using the Meta-Vue® software (Universal Imaging Sys-
tems, Downingtown, Pa., USA).
Mutational Analysis of hMLH1, p53 and PTEN
We sequenced all coding exons and exon-intron boundaries of
hMLH1, p53 and PTEN from leukocyte and tumor DNA. After PCR
amplification, the products were electrophoresed in 0.8% agarose gel
and subjected to cycle sequencing reactions using the Thermo
Sequenase® Fluorescent Cycle Sequencing kit (Amersham Pharma-
cia Biotech). After denaturation, the cycle-sequencing products were
resolved using a denaturing 6.5% Long Ranger polyacrylamide gel on
a sequencing device. Primer sequences and amplification conditions
were described elsewhere and are available from the authors [35–
37].
Methylation Status of the hMLH1 Promoter Region
Leukocyte and tumor DNA were digested with methylation-sen-
sitive or insensitive restriction endonucleases, HpaII (Life Techno-
logies, Karlsruhe, Germany) or MspI (New England Biolabs, Frank-
furt am Main, Germany), respectively. After digestion of 250 ng of
genomic DNA, 25 ng from each digest was used as the template for
PCR amplification of an 829-bp fragment which contains the pro-
moter region, the exon 1 and a part of the intron 1 of the hMLH1 and
harbors five HpaII sites. The amplification products were visualized
using a 1% agarose gel. Primer sequences and PCR conditions were
described previously [23]. The breast cancer cell line CAL51 was
used as positive control [38].
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Table 1. Clinicopathological data and relationship with MSI findings of the 129 analyzed sporadic GBMs
Age range Male/female Previous
astrocytoma
Family or patient
tumor history
Long-term survival
patients, months
MSI-L
!18 years (n = 1) 1/0 0 none 0 0
18–55 years (n = 52) 32/20 8 A–II
3 A–II
1 pinealoma 5/52 (9.6%)
(mean: 55; range: 37–70)
3/52 (5.8%)
155 years (n = 76) 48/28 3 A–I
2 A–II
3 CRC
1 breast cancer
1 NF-2
2/76 (2.6%)
(mean: 59; range: 48–70)
8/76 (10.5%)
A–I = Astrocytoma WHO grade I; A–II = astrocytoma WHO grade II; A–III = astrocytoma WHO grade III; CRC = colorectal cancer;
NF-2 = neurofibromatosis type 2.
LOH Analysis and Semiquantitative PCR Analysis of EGFR
Amplification
LOH at 10q23–24 was studied with the markers D10S215 and
D10S541 (flanking PTEN), PTENCA (PTEN intragenic marker),
D10S583 and D10S579 (telomeric and centromeric to PTEN, re-
spectively). Analysis of LOH at 17p13 (p53) was done with the TP53
and a p53 intragenic marker. Allelic losses at 9p21 (p16/CDKN2A,
p14ARF and p15/CDKN2B) and 13q14 (RB1) were studied with the
primers D9S1748, D9S171, D9S1749, D13S153 and D13S267,
respectively. LOH at 1p35–36 and 19q13 was assessed with the
markers D1S468, D1S482, D19S112 and D19S412 [39, 40]. Primer
sequences and PCR amplification conditions are based on Genome
Database entries (www.gdb.org). To detect EGFR amplification a
differential PCR with the cystic fibrosis transmembrane regulator
(CFTR) gene was carried out, as previously described [40].
Statistical Analysis
Contingency analyses between variables were performed using a
two-tailed Fisher’s exact test and a t test. The relationship between
MSI and other variables was evaluated by multiple regression analy-
sis. Odds ratios (ORs) and 95% confidence intervals (CIs) were
obtained through logistic regression. A value of p ! 0.05 was consid-
ered to be statistically significant.
Results
109 newly diagnosed GBMs and 20 relapses were ana-
lyzed. Sixteen of the 109 newly diagnosed GBM patients
suffered from a previous lower grade astrocytoma (WHO
grades II and/or III). A further 7 patients had a survival
time of more than 36 months after surgery (long-term sur-
vivors). Only 4 patients had a personal history of cancer (3
colorectal carcinoma and 1 breast cancer). There was no
family history of cancer in any of the cases. Detailed clini-
cal data of the patients are presented in table 1.
MSI Status
The total MSI rate was 8.5% (11/129 patients). Low-
level MSI was evidenced in 6 of 109 newly diagnosed
GBMs (5.5%) and in 5 of the 20 relapses (25%) (fig. 1).
MSI-H was not observed. Fourteen of the 1,007 evaluable
dinucleotides (1.4%) and 2 out of 120 evaluable tetranu-
cleotides (1.7%) were unstable. None of the 11 MSI+
tumors showed instability of the mononucleotide repeats.
The most sensitive markers were D5S346 (4/16 unstable
markers), D13S153 (3/16 unstable repeats) and D3S1619
(2/16 instability cases). A statistically significant associa-
tion between MSI and any of the analyzed markers was
not found.
The MSI rate in patients older than 55 years was 9.5%
(this cut-off level showed the lowest p value), and 4.4% in
patients younger than 55 years (p = 0.26). There were no
significant associations between gender and the MSI sta-
tus (p = 0.21).
The presence of MSI in relapsed GBMs was signifi-
cantly higher (p = 0.0274, 95% CI) than in newly diag-
nosed tumors. MSI was more frequently detected in glio-
blastoma patients with a previous low-grade astrocytoma
than in those with clinically de novo glioblastomas (12.5
vs. 6.5%, p = 0.15).
Immunohistochemical Studies
Ten of 11 MSI+ GBMs stained positive for all MMR
proteins. Complete loss of hPMS2 and reduced expres-
sion of hMLH1 were found in a giant-cell GBM (fig. 2),
although only the giant cells were affected. The non-giant
tumor cells stained positive for all MMR proteins. Densi-
tometric analyses of hMLH1 expression was performed in
50 giant tumor cells and compared with hMLH1 expres-
sion in 50 non-giant tumor cells and 50 cells of the nega-
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Fig. 1. Upper row: microsatellite instability
at markers D3S1619 (case G6) and D10S197
(case G1). N and T mean constitutional and
tumor DNA, respectively. Arrow indicates
novel peaks observed in tumor DNA. Lower
row left: loss of heterozygosity at marker
D13S153 (case G11). N and T mean consti-
tutional DNA and tumor DNA. Arrow indi-
cates allelic loss. Lower row right: analysis of
hMLH1 promoter methylation of the giant-
cell GBM (case G5). The HpaII- and MspI-
digested DNA (H and M, respectively)
showed no amplification of the promoter
fragment (829 bp) of hMLH1, indicating no
methylation of the 5 cytosine residues within
the CpG islands of the 5 restriction sites
within the fragment. Leukocyte DNA (B5)
from the patient was also analyzed. As nega-
tive control (NC) we used leukocyte DNA
from a healthy Caucasian adult. The breast
cancer cell line CAL51, which was previous-
ly observed to harbor hMLH1 promoter hy-
permethylation, was used as positive con-
trol. U and W stand for undigested DNA and
water, respectively.
Table 2. Comparative analysis of CIN-mediated pathways in MSI+ and MSS glioblastomas
LOH
p53
Mut.
p53
EGFR
amplification
LOH
PTEN
Mut.
PTEN
Type 1 GBM Type 2 GBM Non-type 1,
non-type 2 GBM
MSI+ GBM 3/11 (27.3%) 1/11 (9.1%) 4/11 (36.4%) 8/11 (72.7%) 2/11 (18.2%) 1/11 (9.1%) 4/11 (36.4%) 6/11 (54.5%)
MSS GBM 4/26 (15.4%) 7/26 (26.9%) 12/26 (46.2%) 21/26 (80.8%) 12/26 (46.2%) 7/26 (26.9%) 12/26 (46.2%) 7/26 (26.9%)
Mut. = Mutation.
tive control. There was a statistically significant differ-
ence of hMLH1 expression between giant cells and non-
giant cells (t test: p = 0.0005).
Analysis of the Sequence and Promoter Methylation of
hMLH1
By sequencing the 19 coding exons and flanking intron
boundaries of the hMLH1 in the giant cell GBM with
reduced hMLH1 expression, neither germline nor somat-
ic genetic alterations were detected. No hMLH1 promoter
fragment appeared from either tumor DNA or constitu-
tional DNA after HpaII digestion, ruling out a hyper-
methylation of the 5 tested cytosine residues in the pro-
moter region of hMLH1 (fig. 1).
Analysis of the CIN-Mediated Pathways
We examined tumor and leukocyte DNA from 37
patients, 11 MSI+ and 26 MSS GBMs as controls. In
MSI+ glioblastomas, the sequence analysis of p53 evi-
denced alterations only in one tumor, a giant cell GBM
(1/11, 9%). Two single base pair exchanges were observed
on exon 5 in codon 175 (CGC→CAC) and exon 6 in
codon 199 (GGA→AGA), predicting the substitution of
histidine for arginine and arginine for glycine, respective-
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Fig. 2. Immunohistochemical studies of hMLH1 (!200), hPMS2 (!200), hMSH2 (!400) and hMSH6 (!400) of
the giant-cell GBM (case G5). Arrows show a reduced expression of hMLH1 and a loss of expression of hPMS2 in the
giant tumor cells (upper row). The non-giant tumor cells show a positive expression of both gene products. Positive
nuclear patterns of hMSH2 and hMSH6 are observed in both giant and non-giant glioblastoma cells (indicated by the
arrow).
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Table 3. Molecular findings in MSI+ glioblastomas
Case Primary/
relapse
MSI Aberrant
MMR protein
EGFR/ CFTR p53 PTEN p15/p16 RB1
G1 Primary D13S153
D10S197
No 1.5 Het
No mutation
Het
No mutation
LOH LOH
G2 Primary MYCL1 No 1.2 Het
No mutation
Het
No mutation
Het n.i.
G3 Primary D18S58 No 18.4 Het
No mutation
LOH 10q23
No mutation
LOH Het
G42 Primary D5S346 No 1.9 n.i. LOH 10q23
No mutation
Het Het
G5 Primary D3S1300
D3S1619
D13S153
D17S250
hMLH1
hPMS2
1.3 LOH 17p13
Mut. codon 175, 199
LOH 10q23
No mutation
Het Het
G6 Primary D3S1619 No 1.6 LOH 17p13
No mutation
Het
No mutation
Het LOH
G7 Relapse D5S346 No 21.1 Het
No mutation
LOH 10q23
No mutation
Het n.i.
G82 Relapse D5S346 No 1.3 Het
No mutation
LOH 10q23
Mut. codon 105
LOH Het
G9 Relapse MYCL1
D5S346
No 29.6 Het
No mutation
LOH 10q23
IVS8+32G1T
Het Het
G10 Relapse D18S58 No 1.4 LOH
No mutation
LOH 10q23
No mutation
Het LOH
G11 Relapse D13S153 No 14.4 Het
No mutation
LOH 10q23
Mut. codon 88
Het LOH
MSI = Microsatellite instability; LOH = loss of heterozygosity; 2 = patients with previous lower grade astrocytoma; Het = allelic balance; n.i. = not informative;
Mut. = mutation; EGFR/ CFTR ratios 13.91 were indicative of EGFR amplification. Aberrant MMR protein is referred to the expression of MMR proteins by
immunohistochemistry.
ly. In this patient, LOH at 17p13 was observed as well.
Two further MSI+ GBMs showed LOH at 17p13 without
p53 sequence alterations. In MSS tumors we detected
mutations of p53 more frequently (7/26, 27%), including
6 single base pair exchanges on exons 2, 4 and 8, which
predicted amino acid substitutions in 5 cases as well as
one deletion on exon 7 (nt 13316_13321delAACAGT).
Table 2 shows the results of the analyses of CIN pathways
in both MSI and MSS GBMs.
Concerning PTEN, mutations in MSI+ GBMs were
observed in 2 cases (2/11, 18%) on exon 5. In MSS glio-
blastomas, mutations of PTEN were detected in 12 of 26
cases (46.2%), consisting in 10 base pair exchanges on
exons 2, 5, 6 and 7, predicting amino acid substitutions in
8 cases. Two acceptor splice site heterozygous mutations
on exon 9 (IVS9–2A1G) were observed as well. The rates
of PTEN mutations were higher in both MSS primary and
MSS relapses compared with primary and relapse MSI+
tumors (38 vs. 14%, p = 0.18 and 54 vs. 25%, p = 0.2,
respectively). LOH at 10q23–24 was found in MSI+ and
MSS GBMs in 72 and 80.7%, respectively.
The EGFR/CFTR ratios of the 11 MSI+ glioblastomas
are displayed in table 3. The cut-off level for a normal
gene copy number (x+3SD) was 3.91. Four of 11 MSI+
GBMs and 12 out of 26 MSS tumors (36.4 and 46.2%,
respectively) showed ratios 13.91, thus indicating amplif-
ication of the EGFR oncogene. In recurrences, amplifica-
tion of EGFR was more frequent in MSI+ tumors than in
MSS GBMs (60 vs. 38%, p = 0.25). In contrast, in primary
glioblastomas we detected a higher rate of EGFR amplifi-
cation in MSS tumors than in MSI+ GBMs (53.8 vs.
16.7%, p = 0.15).
Discussion
The MMR genes play an important role in maintaining
the genetic stability of DNA. Inactivation of these genes
may lead to a mutator phenotype, which has been pro-
posed to promote accumulation of alterations in onco-
genes and tumor suppressor genes [12, 13]. This mutator
phenotype has been observed in HNPCC-associated MSI-
H malignancies as well as in sporadic tumors harboring
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distinct molecular features [26, 27]. Furthermore, sporad-
ic colon cancers showing low-level MSI were found to dis-
play higher rates of K-RAS mutations, MGMT promoter
hypermethylation and a different genome-wide LOH pro-
file than MSS colon carcinomas [41, 42].
A comprehensive study of MSI in the pathogenesis of
GBM including the investigation of the molecular alter-
ations associated with MSI, the involvement of the MMR
system as well as the relationship with the CIN-dependent
events, has not been performed. Some reports analyzed
MSI in glioblastomas either investigating small GBM
series [43–46] or using few microsatellite markers [47].
Contributing to this heterogeneous situation, different
instability criteria and methods were used. We investi-
gated MSI in 129 GBM patients (109 newly diagnosed, 20
relapses) with 15 polymorphic repeats as recommended
by the National Cancer Institute [27] and observed MSI-L
in 11 of 129 (8.5%) GBMs. Similarly to other sporadic
MSI+ non-HNPCC non-colonic cancers such as gastric or
endometrial carcinomas, the most sensitive markers were
dinucleotides, larger repeats such as the tetranucleotide
MYCL1 being only occasionally mutated.
Evaluating the clinicopathological tumor features by
MSI status, we found that the incidence of MSI was more
elevated in patients previously treated for an astrocytoma
WHO grade II or III than in clinically de novo glioblasto-
mas (12.5 vs. 6.5%, p = 0.18). This indicates a trend
between MSI and progression of lower grade astrocyto-
mas to GBM. Similarly, instability was observed to be
more frequent in advanced than in early gastric cancers.
Furthermore, MSI was evidenced in metastatic gastric
cancers, but was absent in neighboring metaplastic epithe-
lium [26].
An aberrant MMR protein expression was found only
in one MSI+ tumor, a giant-cell GBM. This subtype is a
peculiar variant of ordinary GBM, making about 5% of
the total [3, 48]. Interestingly, only the giant cell type
showed these staining alterations, whereas the non-giant
cell type harbored a positive staining. An inactivation of
hMLH1 through mutation or promoter hypermethylation
could not be found. Taking into account the histological
characteristics of giant cell GBM, the possibility that
hMLH1 mutations or hypermethylation of the hMLH1
promoter only affected the giant cell phenotype cannot be
excluded. Alternatively, a transcriptional silencing con-
cerning only the giant cells might also lead to this condi-
tion. The positive expression of MMR proteins in most of
MSI+ tumors remarked the similarities between the MSI+
GBMs and the MSI+ gastric or endometrial carcinomas
regarding instability pattern [49, 50]. This suggests that in
most GBMs MSI might rather be explained by inactiva-
tion of minor MMR genes (for instance, hMSH3 or
hPMS1), mutations leading to a dominant negative phe-
notype as reported for hPMS2 [51] or an imbalance in the
relative amount of MMR proteins as shown for hMSH3
and hMSH6 [52].
Glioblastoma cells may evade growth control mecha-
nisms through CIN-dependent genetic changes such as
aneuploidy, chromosome rearrangements and accumula-
tion of somatic genetic mutations [53, 54]. Two CIN path-
ways were described in the pathogenesis of about 70% of
GBMs, defining type 1 and type 2 GBM [5–7]. In the
present analysis, 55% of the MSI+ tumors displayed a
non-type 1, non-type 2 profile, whereas in the MSS con-
trol group such patterns were found in 27% of the cases.
Nevertheless, since MSI was not observed in all non-type
1, non-type 2 GBM, further molecular alterations should
be responsible for this GBM group. A negative association
between mutations of p53 and MSI was observed and p53
mutations were detected only in one MSI+ giant cell
GBM, which typically shows a higher rate of p53 muta-
tions [48, 55]. Additionally, only missense p53 mutations
were detected but not insertions/deletions at iterated
bases, thus making the possibility that MSI caused p53
alterations unlikely. Similar results emerged from the
analysis of MSI+ gastric carcinomas [19]. PTEN muta-
tions in both primary and relapse GBMs were also found
to be inversely associated with MSI. On the other hand, it
was observed in GBM patients with Turcot syndrome and
germline mutations of MMR genes that both p53 inacti-
vation and chromosomal instability were present in the
glioblastomas, but not in the metachronous colorectal car-
cinomas also developing in these patients [56]. Further-
more, none of the PTEN mutations in MSI+ tumors were
observed in the polyadenine repeat of exon 8, a frequent
target in MSI+ cancers. This finding distinguished the
MSI pattern of GBMs from other MSI+ cancers, such as
endometrial carcinomas, usually showing this type of
PTEN mutation [15, 57]. Amplification of EGFR was
more frequent in MSI+ relapses than in MSS recurrences.
To our knowledge, such relationship has not been re-
ported before.
Less is known about the timing of microsatellite insta-
bility in tumorigenesis. In the present study we detected a
significantly higher MSI rate in relapses compared to pri-
mary tumors (25 vs. 5.5%, p = 0.027). Since all patients
underwent radiotherapy after the first surgical procedure,
a possible explanation is a radiation-induced damage in
the mechanisms of DNA repair. However, by sequencing
p53 and PTEN we did not find alterations such as base
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pair deletions suggesting ionizing radiation-induced DNA
damage. This is in accordance with previous observations
in solid tumors developed after radiotherapy, in which
high chromosomal instability but no MSI could be ob-
served [58].
The present analysis provides evidence that MSI and
chromosomal instability in glioblastoma most likely fol-
low independent pathways, as indicated by the inverse
association between MSI and mutations of p53 and PTEN
as well as the observed mutation types in these genes. The
higher incidence of MSI in relapse GBMs might be com-
patible with a mutator phenotype that could predispose to
the development of recurrences.
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